Drug Approval | November 26, 2021
Aadi Bioscience secures U.S FDA approval of its first product Fyarro
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Owkin builds best-in-class predictive biomedical AI models and robust data sets
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Subscribe To Our Newsletter & Stay Updated
